Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 6/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | APEX1 | P27695 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.31 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.31 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.31 |
| ▸ | ITGAL | P20701 | 1/20 | 0.31 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4454388 | 1.00 | ACE (0.59) | ACEPOLBAPEX1TDP1EGLN1 | |
| SCHEMBL2229670 | 1.00 | ACE (0.59) | ACEPOLBAPEX1TDP1EGLN1 | |
| SCHEMBL247111 | 0.84 | ACE (0.58) | ACEPOLBAPEX1TDP1EGLN1 | |
| SCHEMBL28727117 | 0.84 | ACE (0.58) | ACEPOLBAPEX1TDP1EGLN1 | |
| SCHEMBL1075993 | 0.83 | ACE (0.43) | ACEPIN1 | |
| SCHEMBL28290379 | 0.78 | ACE (0.43) | ACEPOLBAPEX1TDP1 | |
| SCHEMBL6792635 | 0.78 | ACE (0.75) | ACE | |
| SCHEMBL6792627 | 0.78 | ACE (0.75) | ACE | |
| SCHEMBL4885276 | 0.78 | ACE (0.51) | ACEITGB2ICAM1ITGAL | |
| SCHEMBL5127864 | 0.78 | ACE (0.51) | ACEITGB2ICAM1ITGAL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210171520-A1 | EP300/CREBBP INHIBITOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-06-10 | — | — | US | disclosed |
| EP-3643703-A1 | EP300/CREBBP INHIBITOR | Daiichi Sankyo Co., Ltd. (JP) | 2020-04-29 | — | — | EP | disclosed |
| US-20090042854-A1 | Hexahydro-3H-Pyrrolizin-3-Ones Useful as Tachykinin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042854-A1 | Hexahydro-3H-Pyrrolizin-3-Ones Useful as Tachykinin Receptor Antagonists | TACR1, PROKR1, TACR2 | ACE 196/4885POLB 3324/4885APEX1 3021/4885 |
| US-20210171520-A1 | EP300/CREBBP INHIBITOR | EP300, CREBBP, CREB1 | ACE 1439/4885POLB 1653/4885APEX1 2684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.